Skip to main content
SpringerLink
Log in

Im Alter rückt die HIV-Infektion in den Hintergrund

Gute medizinische Versorgung macht’s möglich

  • FORTBILDUNG
  • ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Die Lebenserwartung von HIV-Patienten unterscheidet sich heute nicht mehr von der gleichaltriger nicht HIV-infizierter Menschen. Der Patient selbst ist daher in stärkerem Maße als früher zu eigenverantwortlichem Handeln aufgerufen, während die Behandler mit größtmöglicher Weitsicht agieren müssen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbildung 1
Abbildung 2
Abbildung 4

Literatur

  1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497

    Google Scholar 

  2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421

    Google Scholar 

  3. Antiretrovirale Therapie der HIV-Infektion. Deutsch-Österreichische Leitlinien (Stand März 2010). Available at http://www.daignet.de/site-content/hiv-therapie/leitlinien-1/resolveuid/4e09c351567524bfd215f4d46a9b6f5a. Accessed on 3 January 2012. 2010

  4. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet 2005;366:1059–1062

    Article  PubMed  Google Scholar 

  5. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991;121:293–298

    Article  PubMed  CAS  Google Scholar 

  6. Behrens GM. Abacavir and myocardial infarctions: the benefit of doubt? AIDS 2011;25:2043–2045

    Article  PubMed  Google Scholar 

  7. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008;300:51–59

    Article  PubMed  CAS  Google Scholar 

  8. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112–1115

    Google Scholar 

  9. Buhler S, Sollner J, Seybold U, Bogner JR. [Causes of death in HIV patients]. MMW Fortschr Med 2009;151:56–57

    PubMed  CAS  Google Scholar 

  10. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51–58

    Article  PubMed  CAS  Google Scholar 

  11. Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS 2011;25:1993–2004

    Article  PubMed  CAS  Google Scholar 

  12. De Luca A, Nasi M, Di Giambenedetto S, et al. Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy. J Acquir Immune Defic Syndr 2012

  13. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415–1428

    Article  PubMed  CAS  Google Scholar 

  14. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283–2296

    Article  PubMed  CAS  Google Scholar 

  15. Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008;197:1133–1144

    Article  PubMed  Google Scholar 

  16. European AIDS Clinical Society. Clinical Management and Treatment of HIV-infected Adults in Europe, Prevention and Management of Non-infectious Co-morbidities in HIV, Clinical Management and Treatment of Chronic Hepatitis B and C Coinfection in HIV-infected Adults. Available at http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/eacs-euroguidelines_fullversion.pdf. Accessed on 3 January 2012. 2011

  17. Falutz J. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy. Nat Clin Pract Endocrinol Metab 2007;3:651–661

    Article  PubMed  CAS  Google Scholar 

  18. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993–2003

    Article  PubMed  Google Scholar 

  19. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study. AIDS 2003;17:1179–1193

    Article  PubMed  Google Scholar 

  20. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723–1735

    Article  PubMed  Google Scholar 

  21. Grinspoon S. Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome. Clin Infect Dis 2003;37 Suppl 2:S85–90

    Article  PubMed  CAS  Google Scholar 

  22. Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC, Jr., Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433–438

    Article  PubMed  Google Scholar 

  23. Grunfeld C, Delaney JA, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009;23:1841–1849

    Article  PubMed  Google Scholar 

  24. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008;5:e203

    Article  PubMed  Google Scholar 

  25. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008;48:590–598

    Article  PubMed  Google Scholar 

  26. Lundgren JD, Babiker A, El-Sadr W, et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis 2008;197:1145–1155

    Article  PubMed  Google Scholar 

  27. Moebus S, Hanisch JU, Aidelsburger P, et al. Impact of 4 different definitions used for the assessment of the prevalence of the Metabolic Syndrome in primary healthcare: The German Metabolic and Cardiovascular Risk Project (GEMCAS). Cardiovasc Diabetol 2007;6:22

    Article  PubMed  Google Scholar 

  28. Plaeger SF, Collins BS, Musib R, et al. Immune Activation in the Pathogenesis of Treated Chronic HIV Disease: A Workshop Summary. AIDS Res Hum Retroviruses 2011

  29. Pou KM, Massaro JM, Hoffmann U, et al. Patterns of abdominal fat distribution: the Framingham Heart Study. Diabetes Care 2009;32:481–485

    Article  PubMed  Google Scholar 

  30. Rasmussen LD, Engsig FN, Christensen H, et al. Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. AIDS 2011;25:1637–1646

    Article  PubMed  Google Scholar 

  31. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371:1417–1426

    Article  PubMed  CAS  Google Scholar 

  32. Saves M, Raffi F, Capeau J, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002;34:1396–1405

    Article  PubMed  CAS  Google Scholar 

  33. Scherzer R, Heymsfield SB, Lee D, et al. Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS 2011;25:1405–1414

    Article  PubMed  Google Scholar 

  34. Scholze J, Alegria E, Ferri C, et al. Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model. BMC Public Health 2010;10:529

    Article  PubMed  Google Scholar 

  35. Tebas P, Henry WK, Matining R, et al. Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. PLoS One 2008;3:e2021

    Article  PubMed  Google Scholar 

  36. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998;12:F167–173

    Article  PubMed  CAS  Google Scholar 

  37. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010;201:318–330

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MUC Research GmbH, Karlsplatz 8, D-80335, München, Deutschland

    Birgit Mück

  2. MUC Research GmbH, MVZ Karlsplatz, München, Deutschland

    Gesa Trapana &  Hans Jäger

Authors
  1. Birgit Mück
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gesa Trapana
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hans Jäger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Birgit Mück.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mück, B., Trapana, G. & Jäger, H. Im Alter rückt die HIV-Infektion in den Hintergrund. MMW - Fortschritte der Medizin 154, 26–29 (2012). https://doi.org/10.1007/s15006-012-0622-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-012-0622-1

Keywords - HIV in elderly

Search

Navigation